natgillin/translations-raw huggingface dataset:
Almindeligt: kvalme/ opkastning, unormal vandladning, træthed, svimmelhed (også når man rejser sig fra liggende eller siddende stilling) og blodprøver, der viser en forhøjet mængde af et enzym, der måler muskel - og hjertefunktionen (kreatinkinase) eller stigning i stoffer, som måler nyrefunktionen (carbamid, kreatinin).
Common: nausea/ vomiting, abnormal urination, fatigue and dizziness (including when getting up from a lying or sitting position) and blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine).
Ikke almindeligt: diarré, lavt blodtryk, besvimelse, hjertebanken, rødmen, hævelse og problemer med seksuel formåen.
Uncommon: diarrhoea, low blood pressure, fainting, heart rate increased, flushing, swelling and sexual dysfunction (problems with sexual performance).
Blodprøver kan vise nedsat mængde af kalium og natrium i blodet.
Blood tests may show lowered levels of potassium and sodium in your blood.
Der er indberettet bivirkninger efter markedsføring af CoAprovel, men det vides ikke hvor ofte de forekommer.
Some undesirable effects have been reported since the marketing of CoAprovel but the frequency for them to occur is not known.
Hovedpine, ringen for ørerne, hoste, smagsforstyrrelser, forstoppelse, led - og muskelsmerter, leversygdom og nedsat nyrefunktion, øget mængde af kalium i blodet, allergiske reaktioner (såsom udslæt, nældefeber, opsvulmet ansigt, læber, mund, tunge og hals.
These undesirable effects are: headache, ringing in the ears, cough, taste disturbance, indigestion, pain in joints and muscles, liver function abnormal and impaired kidney function, increased level of potassium in your blood and allergic reactions such as rash, hives, swelling of the face, lips, mouth, tongue or throat.
Der er hos patienter, der tager irbesartan alene, også indberettet brystsmerter.
In patients taking irbesartan alone, in addition to the side effects listed above, chest pain has also been reported.
Yderligere bivirkninger, der er tilknyttet det andet aktive stof i CoAprovel (hydrochlorthiazid) alene er: appetitmangel; maveirritation; mavekramper; forstoppelse; gulsot, hvor hud og/ eller det hvide i øjne bliver gulfarvet; bugspytkirtelbetændelse, med stærke smerter i øvre maveregion, ofte forbundet med kvalme og opkastning; søvnproblemer; depression; sløret syn; mangel på hvide blodceller, som kan resultere i hyppige infektioner; feber; nedsat antal blodplader (blodceller, som er nødvendige for, at blodet kan størkne); nedsat antal af røde blodceller (blodmangel), som karakteriseres ved træthed, hovedpine, forpustethed ved motion, svimmelhed og bleghed; nyresygdom; lungeproblemer, inklusive lungebetændelse og væske i lunger; øget følsomhed af huden for sol; årebetændelse; hudsygdom som karakteriseres ved afskalning af huden over hele kroppen; kutan lupus erythematosus, som ses i form af udslæt i ansigt, hals og hovedbund; allergiske reaktioner; svækkelse og muskelkramper; ændring i puls; nedsat blodtryk efter ændringer i kropsstilling; hævelse af spytkirtler; højt sukkerindhold i blodet; sukker i urinen; øgning i bestemte typer af fedt i blod; høj mængde urinsyre i blodet, som kan lede til gigt.
Additional side effects associated with the other component of CoAprovel (hydrochlorothiazide) alone are: loss of appetite; stomach irritation; stomach cramps; constipation; jaundice seen as yellowing of the skin and/ or whites of the eyes; inflammation of the pancreas characterised by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; lack of white blood cells, which can result in frequent infections, fever; decrease in the number of platelets (a blood cell essential for the clotting of the blood), decreased number of red blood cells (anaemia) characterised by tiredness, headaches, being short of breath when exercising, dizziness and looking pale; kidney disease; lung problems including pneumonia or build-up of fluid in the lungs; increased sensitivity of the skin to the sun; inflammation of blood vessels; a skin disease characterized by the peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that may appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasm; altered heart rate; reduced blood pressure after a change in body position; swelling of the salivary glands; high sugar levels in the blood; sugar in the urine; increases in some kinds of blood fat; high uric acid levels in the blood, which may cause gout.
De bivirkninger, der er forbundet med hydrochorthiazid, kan blive forstærket ved højere doser.
It is known that side effects associated with hydrochlorothiazide may increase with higher doses of hydrochlorothiazide.
OPBEVARING
HOW TO STORE COAPROVEL
Brug ikke CoAprovel efter den udløbsdato, der står på pakningen.
Do not use CoAprovel after the expiry date which is stated on the carton and on the blister after EXP.
Opbevares i den originale yderpakning for at beskytte mod fugt.
90 Store in the original package in order to protect from moisture.
Aktive stoffer: irbesartan og hydrochlorthiazid.
What CoAprovel contains The active substances are irbesartan and hydrochlorothiazide.
Hver tablet af CoAprovel 150 mg/ 12, 5 mg tabletter indeholder 150 mg irbesartan og 12, 5 mg hydrochlorthiazid.
Each tablet of CoAprovel 150 mg/ 12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.
Øvrige indholdsstoffer: mikrokrystallinsk cellulose, croscarmellosenatrium, lactosemonohydrat, magnesiumstearat, silica kolloidt, prægelatineret majsstivelse, rød og gul jernoxid (E172).
The other ingredients are microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica, pregelatinised maize starch, red and yellow ferric oxides (E172).
Udseende og pakningsstørrelser CoAprovel 150 mg/ 12, 5 mg tabletter er ferskenfarvet, bikonvekse, ovalformede med et hjerte præget på den ene side og nummeret 2775 på den anden side.
What CoAprovel looks like and contents of the pack CoAprovel 150 mg/ 12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side.
CoAprovel 150 mg/ 12, 5 mg tabletter leveres i blisterpakninger á 14, 28, 56 eller 98 tabletter.
CoAprovel 150 mg/ 12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets.
Indehaver af markedsføringstilladelsen SANOFI PHARMA BRISTOL- MYERS SQUIBB SNC 174 avenue de France F- 75013 Paris - Frankrig
Marketing Authorisation Holder SANOFI PHARMA BRISTOL-MYERS SQUIBB SNC 174 avenue de France F-75013 Paris - France
Fremstiller SANOFI WINTHROP INDUSTRIE 1, rue de la Vierge Ambarès & Lagrave F- 33565 Carbon Blanc Cedex - Frankrig
Manufacturer SANOFI WINTHROP INDUSTRIE 1, rue de la Vierge Ambarès & Lagrave F-33565 Carbon Blanc Cedex - France
91 Hvis du vil have yderligere oplysninger om CoAprovel, skal du henvende dig til den lokale repræsentant:
91 For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Du kan finde yderligere information om CoAprovel på Det europæiske Lægemiddelagenturs (EMEAs) hjemmeside http: // www. emea. europa. eu /
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/
93 INDLÆGSSEDDEL:
93 PACKAGE LEAFLET:
INFORMATION TIL BRUGEREN CoAprovel 300 mg/ 12, 5 mg tabletter irbesartan/ hydrochlorthiazid
INFORMATION FOR THE USER CoAprovel 300 mg/ 12.5 mg tablets irbesartan/ hydrochlorothiazide
94 hvis du lider af sukkersyge hvis du lider af erytematøs lupus (også kaldet lupus eller systemisk lupus erythematosus) hvis du lider af primær aldosteronisme (tilstand med høj produktion af hormonet aldosteron, som gør, at der ophobes natriumsalt i kroppen, og blodtrykket derfor stiger)
94 if you suffer from liver problems if you suffer from diabetes if you suffer from lupus erythematosus (also known as lupus or SLE) if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).
95 Din læge vil normalt beslutte, at du skal stoppe med at tage CoAprovel, så snart du ved, at du er gravid.
95 Your doctor will normally advise you to stop taking CoAprovel as soon as you know you are pregnant.
Den sædvanlige dosis af CoAprovel er en tablet dagligt.
Dosage The usual dose of CoAprovel is one tablet a day.
96 Almindelig:
96 The frequency of the side effects listed below is defined using the following convention:
Spørg på apoteket, hvordan du skal aflevere medicinrester.
Store in the original package in order to protect from moisture.
97 6.
97 Medicines should not be disposed of via wastewater or household waste.
Hver tablet af CoAprovel 300 mg/ 12, 5 mg tabletter indeholder 300 mg irbesartan og 12, 5 mg hydrochlorthiazid.
Each tablet of CoAprovel 300 mg/ 12.5 mg contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide.
Udseende og pakningsstørrelser CoAprovel 300 mg/ 12, 5 mg tabletter er ferskenfarvet, bikonvekse, ovalformede med et hjerte præget på den ene side og nummeret 2776 på den anden side.
What CoAprovel looks like and contents of the pack CoAprovel 300 mg/ 12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2776 engraved on the other side.
CoAprovel 300 mg/ 12, 5 mg tabletter leveres i blisterpakninger á 14, 28, 56 eller 98 tabletter.
CoAprovel 300 mg/ 12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets.
SANOFI WINTHROP INDUSTRIE 30- 36 Avenue Gustave Eiffel 37100 Tours - Frankrig
SANOFI WINTHROP INDUSTRIE 30-36 Avenue Gustave Eiffel 37100 Tours - France
98 Hvis du vil have yderligere oplysninger om CoAprovel, skal du henvende dig til den lokale repræsentant:
98 For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
100 INDLÆGSSEDDEL:
100 PACKAGE LEAFLET:
INFORMATION TIL BRUGEREN CoAprovel 150 mg/ 12, 5 mg filmovertrukne tabletter irbesartan/ hydrochlorthiazid
INFORMATION FOR THE USER CoAprovel 150 mg/ 12.5 mg film-coated tablets irbesartan/ hydrochlorothiazide
101 hvis du lider af sukkersyge hvis du lider af erytematøs lupus (også kaldet lupus eller systemisk lupus erythematosus) hvis du lider af primær aldosteronisme (tilstand med høj produktion af hormonet aldosteron, som gør, at der ophobes natriumsalt i kroppen, og blodtrykket derfor stiger)
101 if you suffer from liver problems if you suffer from diabetes if you suffer from lupus erythematosus (also known as lupus or SLE) if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).
102 Din læge vil normalt beslutte, at du skal stoppe med at tage CoAprovel, så snart du ved, at du er gravid.
102 Your doctor will normally advise you to stop taking CoAprovel as soon as you know you are pregnant.
Almindelig:
103 The frequency of the side effects listed below is defined using the following convention:
Opbevares i den originale yderpakning for at beskytte mod fugt.
104 Store in the original package in order to protect from moisture.
104 6.
6.
De aktive stoffer er irbesartan og hydrochlorthiazid.
What CoAprovel contains The active substances are irbesartan and hydrochlorothiazide.
Hver tablet af CoAprovel 150 mg/ 12, 5 mg tabletter indeholder 150 mg irbesartan og 12, 5 mg hydrochlorthiazid.
Each film-coated tablet of CoAprovel 150 mg/ 12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.
Udseende og pakningsstørrelser CoAprovel 150 mg/ 12, 5 mg filmovertrukne tabletter er ferskenfarvet, bikonvekse, ovalformede med et hjerte præget på den ene side og nummeret 2875 på den anden side.
What CoAprovel looks like and contents of the pack CoAprovel 150 mg/ 12.5 mg film-coated tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2875 engraved on the other side.
CoAprovel 150 mg/ 12, 5 mg filmovertrukne tabletter leveres i blisterpakninger á 14, 28, 30, 56, 84, 90 eller 98 filmovertrukne tabletter.
CoAprovel 150 mg/ 12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets.
105 Hvis du vil have yderligere oplysninger om CoAprovel, skal du henvende dig til den lokale repræsentant:
105 For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
107 INDLÆGSSEDDEL:
107 PACKAGE LEAFLET:
INFORMATION TIL BRUGEREN CoAprovel 300 mg/ 12, 5 mg filmovertrukne tabletter irbesartan/ hydrochlorthiazid
INFORMATION FOR THE USER CoAprovel 300 mg/ 12.5 mg film-coated tablets irbesartan/ hydrochlorothiazide
108 hvis du lider af sukkersyge hvis du lider af erytematøs lupus (også kaldet lupus eller systemisk lupus erythematosus) hvis du lider af primær aldosteronisme (tilstand med høj produktion af hormonet aldosteron, som gør, at der ophobes natriumsalt i kroppen, og blodtrykket derfor stiger)
108 if you suffer from liver problems if you suffer from diabetes if you suffer from lupus erythematosus (also known as lupus or SLE) if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).
109 Din læge vil normalt beslutte, at du skal stoppe med at tage CoAprovel, så snart du ved, at du er gravid.
109 Your doctor will normally advise you to stop taking CoAprovel as soon as you know you are pregnant.
1 til 10 patienter ud af 100 Ikke almindlig:
110 The frequency of the side effects listed below is defined using the following convention:
111 6.
111 Medicines should not be disposed of via wastewater or household waste.
Hver tablet af CoAprovel 300 mg/ 12, 5 mg tabletter indeholder 300 mg irbesartan og 12, 5 mg hydrochlorthiazid.
Each film-coated tablet of CoAprovel 300 mg/ 12.5 mg contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide.
Udseende og pakningsstørrelser CoAprovel 300 mg/ 12, 5 mg filmovertrukne tabletter er ferskenfarvet, bikonvekse, ovalformede med et hjerte præget på den ene side og nummeret 2876 på den anden side.
What CoAprovel looks like and contents of the pack CoAprovel 300 mg/ 12.5 mg film-coated tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2876 engraved on the other side.
CoAprovel 300 mg/ 12, 5 mg filmovertrukne tabletter leveres i blisterpakninger á 14, 28, 30, 56, 84, 90 eller 98 filmovertrukne tabletter.
CoAprovel 300 mg/ 12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets.
112 Hvis du vil have yderligere oplysninger om CoAprovel, skal du henvende dig til den lokale repræsentant:
112 For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
114 INDLÆGSSEDDEL:
114 PACKAGE LEAFLET:
INFORMATION TIL BRUGEREN CoAprovel 300 mg/ 25 mg filmovertrukne tabletter irbesartan/ hydrochlorthiazid
INFORMATION FOR THE USER CoAprovel 300 mg/ 25 mg film-coated tablets irbesartan/ hydrochlorothiazide
115 hvis du lider af sukkersyge hvis du lider af erytematøs lupus (også kaldet lupus eller systemisk lupus erythematosus) hvis du lider af primær aldosteronisme (tilstand med høj produktion af hormonet aldosteron, som gør, at der ophobes natriumsalt i kroppen, og blodtrykket derfor stiger)
115 if you suffer from liver problems if you suffer from diabetes if you suffer from lupus erythematosus (also known as lupus or SLE) if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).
116 Din læge vil normalt beslutte, at du skal stoppe med at tage CoAprovel, så snart du ved, at du er gravid.
116 Your doctor will normally advise you to stop taking CoAprovel as soon as you know you are pregnant.
1 til 10 patienter ud af 100 Ikke almindlig:
117 The frequency of the side effects listed below is defined using the following convention:
118 6.
118 Medicines should not be disposed of via wastewater or household waste.
Hver tablet af CoAprovel 300 mg/ 25 mg tabletter indeholder 300 mg irbesartan og 25 mg hydrochlorthiazid.
Each film-coated tablet of CoAprovel 300 mg/ 25 mg contains 300 mg irbesartan and 25 mg hydrochlorothiazide.
Udseende og pakningsstørrelser CoAprovel 300 mg/ 25 mg filmovertrukne tabletter er lyserød, bikonvekse, ovalformede med et hjerte præget på den ene side og nummeret 2788 på den anden side.
What CoAprovel looks like and contents of the pack CoAprovel 300 mg/ 25 mg film-coated tablets are pink, biconvex, oval-shaped, with a heart debossed on one side and the number 2788 engraved on the other side.
CoAprovel 300 mg/ 25 mg filmovertrukne tabletter leveres i blisterpakninger á 14, 28, 30, 56, 84, 90 eller 98 filmovertrukne tabletter.
CoAprovel 300 mg/ 25 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets.
119 Hvis du vil have yderligere oplysninger om CoAprovel, skal du henvende dig til den lokale repræsentant:
119 For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
EU- nummre
EU Number
150 mg lamivudine 300 mg zidovudine
150 mg lamivudine 300 mg zidovudine
blisterpakning (PVC/ alu)
Blister (PVC/ alu)
Flaske (HDPE)
Bottle (HDPE)
Combivir er et lægemiddel, der indeholder to aktive stoffer, lamivudin (150 mg) og zidovudin (300 mg).
Combivir is a medicine that contains two active substances, lamivudine (150 mg) and zidovudine (300 mg).
Det leveres som hvide, kapselformede tabletter.
It is available as white capsule-shaped tablets.
Combivir er et antiviralt lægemiddel.
Combivir is an antiviral medicine.
Dette virus er årsag til aids (erhvervet immundefektsyndrom).
It is used in combination with at least one other antiviral medicine to treat patients who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
Behandlingen med Combivir bør indledes af en læge med erfaring i behandling af hiv- infektion.
Treatment with Combivir should be initiated by a doctor who has experience in the management of HIV infection.
Til voksne og unge med en legemsvægt på mindst 30 kg er den anbefalede dosis Combivir én tablet to gange dagligt.
In adults and adolescents weighing at least 30 kg, the recommended dose of Combivir is one tablet taken twice a day.
Til børn på mellem 14 og 30 kg afhænger antallet af tabletter og halve tabletter, der skal tages, af legemsvægten.
In children weighing between 14 and 30 kg, the number of tablets and half tablets to take depends on body weight.
Børn, der vejer under 14 kg skal anvende særskilte orale opløsninger, som indeholder lamivudin og zidovudin.
Children weighing less than 14 kg will need to use separate oral solutions containing lamivudine and zidovudine.
Bivirkningerne hos børn, som får Combivir, skal overvåges nøje.
Children taking Combivir should be closely monitored for side effects.
Combivir kan tages sammen med et måltid eller mellem måltiderne.
Combivir can be taken with or without food.
Patienter, der ikke kan sluge tabletter, bør anvende den orale opløsning, eller knuse tabletterne og komme dem i lidt mad eller drikke, umiddelbart inden de tager dosen.
The tablets should ideally be swallowed without crushing, although patients who cannot swallow tablets may crush and add them to a small amount of food or drink, before taking the dose immediately.
Hvis en patient skal holde op med at tage lamivudin eller zidovudin eller skal have ændret dosis på grund af problemer med nyrerne, leveren ellerf blodet, må patienten tage medicin indeholdende lamivudin eller zidovudin hver for sig.
If patients need to stop taking lamivudine or zidovudine, or need to take different doses because of problems with their kidneys, liver or blood, they will need to take medicines containing lamivudine or zidovudine separately.
Begge aktive stoffer i Combivir, lamivudin og zidovudin, er reverse transcriptase- hæmmere af nukleosidtypen.
Both active substances in Combivir, lamivudine and zidovudine, are nucleoside reverse transcriptase inhibitors (NRTIs).
De virker begge ved at blokere reverse transcriptase, et enzym, der produceres af hiv og gør det muligt for viruset at inficere celler og producere flere virus.
They both work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Combivir i kombination med mindst ét andet antiviralt lægemiddel nedsætter hiv- mængden i blodet og holder den nede.
Combivir, taken in combination with at least one other antiviral medicine, reduces the amount of HIV in the blood and keeps it at a low level.
Combivir helbreder ikke hiv- infektion eller aids, men kan sinke den skade på immunsystemet og de infektioner og sygdomme, der er forbundet med aids.
Combivir does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Reproduction is authorised provided the source is acknowledged Hvordan blev Combivir undersøgt?
How has Combivir been studied?
Da zidovudin har været på markedet i Den Europæiske Union (EU) siden midten af 1980' erne, og da lamivudin har været godkendt i EU siden 1996 som Epivir, har virksomheden fremlagt oplysninger fra tidligere undersøgelser, hvor de to stoffer blev givet sammen.
Because zidovudine has been available in the European Union (EU) since the mid-1980s, and lamivudine has been approved in the EU since 1996 as Epivir, the company presented information obtained in earlier studies of the two substances taken together.
Virksomheden foretog desuden en sammenligning af kombinationstabletten med separate tabletter med lamivudin og zidovudin hos 75 voksne og unge, der ikke tidligere havde været behandlet for hiv- infektion.
The company also compared the combination tablet to separate tablets of lamivudine and zidovudine in 75 adults and adolescents who had not taken treatment for HIV infection before.
Behandlingens virkning blev hovedsagelig bedømt ved ændringen i hiv- indhold i blodet (virusmængden) og ændringen i antal CD4 T- celler i blodet CD4- celletallet efter 12 ugers behandling.
The main measures of effectiveness were the change in the level of HIV in the blood (viral load) and the change in the number of CD4 T-cells in the blood (CD4 cell count) after 12 weeks of treatment.
CD4 T- celler er hvide blodlegemer, der er vigtige i bekæmpelsen af infektioner, men som dræbes af hiv.
CD4 T-cells are white blood cells that are important in helping to fight infections, but which are killed by HIV.
Virksomheden undersøgte desuden, hvordan kroppen absorberer den kombinerede tablet i forhold til de separate tabletter.
The company also looked at the way the combined tablet was absorbed in the body in comparison with the separate tablets.
For at understøtte sine anbefalinger vedrørende Combivir- dosen til børn fremlagde firmaet oplysninger fra undersøgelser af blodets indhold af lamivudin og zidovudin hos børn, der får lægemidlerne hver for sig.
In order to support its recommendations for Combivir doses in children, the company presented information from studies of the levels of lamivudine and zidovudine in the blood of children taking the medicines separately.
Firmaet forelagde desuden oplysninger om det forventede indhold af de to stoffer i blodet hos børn, der får de to stoffer samlet i én tablet.
It also presented information on the predicted blood levels of the two substances in children taking the two substances combined in one tablet.
Combivir var effektivt til at nedsætte virusindholdet og få CD4- celletallet til at stige.
Combivir was effective at reducing viral loads and allowing CD4 cell counts to rise.